Clinical trial
Daclizumab to Treat Wegener's Granulomatosis
NCT00040248 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00040248 |
|---|---|
| Title | Daclizumab to Treat Wegener's Granulomatosis |
| Official title | A Randomized Trial Examining the Use of Daclizumab in Wegener's Granulomatosis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Wegener's Granulomatosis |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 75 |
| Start date | Jun 1, 2002 |
| Completion | May 1, 2005 |
| First posted | Jun 24, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: